Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.
Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.
复制标题
DOI：
10.1111/jcmm.17297
复制
发表时间：
2022-05
影响因子：
5.3
通讯作者：
中科院分区：
文献类型：
--
作者：
Despite significant efficacy of ibrutinib therapy in mantle cell lymphoma (MCL), about one‐third of MCL patients will display primary resistance. In time, secondary resistance occurs almost universally with an unlikely response to salvage chemotherapy afterwards. While intense efforts are being directed towards the characterization of resistance mechanisms, our focus is on identifying the signalling network rewiring that characterizes this ibrutinib resistant phenotype. Importantly, intrinsic genetic, epigenetic and tumour microenvironment‐initiated mechanisms have all been shown to influence the occurrence of the ibrutinib resistant phenotype. By using in vitro and in vivo models of primary and secondary ibrutinib resistance as well as post‐ibrutinib treatment clinical samples, we show that dual targeting of the BCL‐2 and PI3‐kinase signalling pathways results in synergistic anti‐tumour activity. Clinically relevant doses of venetoclax, a BCL‐2 inhibitor, in combination with duvelisib, a PI3Kδ/γ dual inhibitor, resulted in significant inhibition of these compensatory pathways and apoptosis induction. Our preclinical results suggest that the combination of venetoclax and duvelisib may be a therapeutic option for MCL patients who experienced ibrutinib failure and merits careful consideration for future clinical trial evaluation.
登录
查看更多内容
DOI：
10.1056/nejmoa1513257
发表时间：
2016-01-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Roberts AW;Davids MS;Pagel JM;Kahl BS;Puvvada SD;Gerecitano JF;Kipps TJ;Anderson MA;Brown JR;Gressick L;Wong S;Dunbar M;Zhu M;Desai MB;Cerri E;Heitner Enschede S;Humerickhouse RA;Wierda WG;Seymour JF
通讯作者：
Seymour JF
影响因子：
20.3
作者：
Liu, Ta-Ming;Woyach, Jennifer A.;Johnson, Amy J.
通讯作者：
Johnson, Amy J.
影响因子：
64.8
作者：
Vasan N;Baselga J;Hyman DM
通讯作者：
Hyman DM
影响因子：
11.5
作者：
Markham, Anthony
通讯作者：
Markham, Anthony
影响因子：
11.5
作者：
Miller, Barry W.;Przepiorka, Donna;Pazdur, Richard
通讯作者：
Pazdur, Richard